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Abstract
A subset of human papillomavirus (HPV) infections is causally related to the development of human epithelial tumors and
cancers. Like a number of pathogens, HPV entry into target cells is initiated by first binding to heparan sulfonated
proteoglycan (HSPG) cell surface attachment factors. The virus must then move to distinct secondary receptors, which are
responsible for particle internalization. Despite intensive investigation, the mechanism of HPV movement to and the nature
of the secondary receptors have been unclear. We report that HPV16 particles are not liberated from bound HSPG
attachment factors by dissociation, but rather are released by a process previously unreported for pathogen-host cell
interactions. Virus particles reside in infectious soluble high molecular weight complexes with HSPG, including syndecan-1
and bioactive compounds, like growth factors. Matrix mellatoproteinase inhibitors that block HSPG and virus release from
cells interfere with virus infection. Employing a co-culture assay, we demonstrate HPV associated with soluble HSPG-growth
factor complexes can infect cells lacking HSPG. Interaction of HPV-HSPG-growth factor complexes with growth factor
receptors leads to rapid activation of signaling pathways important for infection, whereas a variety of growth factor
receptor inhibitors impede virus-induced signaling and infection. Depletion of syndecan-1 or epidermal growth factor and
removal of serum factors reduce infection, while replenishment of growth factors restores infection. Our findings support an
infection model whereby HPV usurps normal host mechanisms for presenting growth factors to cells via soluble HSPG
complexes as a novel method for interacting with entry receptors independent of direct virus-cell receptor interactions.
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Introduction
Human papillomaviruses (HPVs) are small, DNA-containing
viruses that infect mucosal and cutaneous epithelium to cause
benign and malignant tumors, including many anogenital,
oropharyngeal and some skin cancers [1,2]. HPVs demonstrate
remarkable host restrictions and have strict tropism for stratifying
squamous epithelium. HPV virions consist of 360 copies of the L1
capsid protein, 12–72 copies of the L2 protein and the circular
viral genome (<8 kb) condensed by cellular histones. Like a
number of other pathogens, HPV entry into target cells is a
multistep process initiated by binding to cell surface attachment
factors, the most common of which are glycosaminoglycan chains,
especially heparan sulfate in proteoglycans (HSPGs) [3,4]. Binding
to these negatively charged polysaccharides is usually electrostatic
and relatively nonspecific. Many microbes like HPVs must transfer
from HSPG to a distinct secondary receptor responsible for active
pathogen internalization [5]. For HPVs this entry receptor has
been elusive. Despite intensive investigation, the mechanism of
HPV movement from primary HSPG attachment receptors to
secondary high-affinity receptors has been unclear.
Several studies suggest a role for HPV L2 protein in facilitating
infection via interaction with a secondary receptor (reviewed in ref.
[6]). In this model, initial virus attachment to HSPG causes a
conformational change in L1 that facilitates a critical proteolytic
cleavage of L2 by furin, a proprotein convertase [6–8]. L2
cleavage is thought to expose the L2 binding site for the secondary
cell receptor, lowering the affinity of L1 for HSPG binding and
resulting in transfer to the entry receptor [8]. Many, but not all, of
the accumulating experimental data support this attractive
hypothesis. Although antibodies raised to L2 can neutralize
infection [9] and in vitro synthesized L2 peptides and proteins
can interact with the cell surface [10,11], there is no direct
evidence that L2 in the context of the virion has a function at the
cell plasma membrane. Scatchard plot analyses indicate high
affinity binding of HPV33 VLP to HeLa cells, with a Kd of
,85610
212 M [12]. This strong binding affinity of L1 VLP for
cells makes it difficult to conceive how cleavage of L2, which is not
involved in primary binding, could change the affinity of L1 so
dramatically as to cause particle dissociation from the HS chain.
Moreover, a recent report shows that heparin binding does not
induce obvious conformational changes in the HPV16 capsid
structure in vitro, except for slight movements of the surface loops
and the residues directly involved in oligosaccharide binding [13].
Additional observations that call into question a function for L2 in
early entry steps include the fact that L1-only containing virus-like
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16] and PsVs containing a furin-resistant L2 mutant bind, enter,
and uncoat in the endosome [7]. Finally, furin cleaved HPV
particles can be rendered non-infectious by heparinase treatment,
suggesting that furin does more than simply altering HPV L2
proteins [17]. These various observations illustrate the uncertainty
of how HPV particles move from HSPGs to an internalization
receptor.
Syndecan-1 is the most abundant HSPG in keratinocytes and is
an HPV attachment receptor [18,19]. Syndecans possess enor-
mous molecular and functional diversity owing to modifications of
their HS chains by sulfate groups that vary in sulfation degree,
length, charge and sugar composition as well as by covalent
attachment of chondroitin sulfate chains [20]. These modifications
facilitate the interaction of syndecans and other HSPG with a
variety of ligands including growth factors (GFs), cytokines,
chemokines, extracellular matrix (ECM) proteins, proteinases
and their inhibitors, viruses from such Families as Retroviridae,
Herpesviridae, Papillomavirdae and Flaviviridae, as well as several
bacterial pathogens [21,22]. This range of ligand interactions
allows HSPG and syndecans to participate in many different
cellular activities, including organogenesis, GF and cytokine
binding, cellular adhesion, and wound healing. By binding soluble
GFs, syndecans are able to concentrate these ligands on or near
cells and present them to their high affinity cell surface receptors
(depicted in Figure 1A) [23,24].
A prominent characteristic of syndecans is that their extracel-
lular domains can be cleaved to release intact HS-containing
ectodomains decorated with bioactive molecules that act as soluble
effectors [25,26]. All syndecan ectodomains are shed constitutively
as a normal part of turnover, but this process is also regulated (e.g.,
certain GFs accelerate shedding). The enzymes responsible for
syndecan shedding are the matrix metalloproteinase peptidases
(MMPs) that cleave the syndecan core protein and release the
ectodomains (Figure 1A i). MMPs comprise a family of over 25
endopeptidases capable of cleaving all kinds of ECM proteins and
cell surface receptors; MMPs also can process a number of
bioactive molecules [27]. The HS moieties on syndecans also can
be processed by heparinases, which can liberate the HS bound to
GFs and bioactive compounds. The many biological functions of
shedding syndecans have been summarized in several excellent
reviews [21,23,28].
Because HPVs are known to interact with HSPGs like
syndecan-1 at the cell surface and on the ECM, we investigated
whether virus particles bound to these molecules could be released
in association with HSPG complexes containing bioactive
molecules like GFs. Although syndecan-1 HSPGs associate with
a number of soluble biological mediators to present them to their
high affinity binding receptors [21], we chose to focus on
epidermal growth factor (EGF) and fibroblast growth factor 7
(FGF7, also known as keratinocyte growth factor [KGF]) and their
cognate receptors EGFR and KGFR (FGFR2IIIb). These
receptors are abundant GFRs on human keratinocytes and play
vital roles during wound healing [29], an important mediator of
HPV infection of epithelial surfaces [30]. Further, syndecan-1
interactions with EGFR and KGFR ligands are well characterized
[21]. We hypothesized that the normal cellular mechanism
involving HSPG-GF/bioactive complex release from cells might
help explain how HPVs transfer to secondary internalization
receptors.
Herein we describe two novel findings with respect to initial
HSPG binding by a pathogen and movement to specific uptake
receptors on host cells. First, we show that HPV particles bound
initially to cell surface HSPGs are released as soluble and
infectious high molecular weight (HMW) complexes with HSPGs
and GFs. Second, we provide evidence that the HPV-HS-GF
complexes activate signaling cascades that are important media-
tors of HPV infection of human keratinocytes. The data support a
model whereby HPVs bind to uptake receptors indirectly via aG F
bridge between the virus and the cognate GFR.
Results
MMPs contribute to cell surface release of HPV, which is
important for infection
Confocal microscopy and immunoprecipitation (IP) were used
to verify HPV16 and HPV31 particles bind to syndecan-1 on
HaCaT human keratinocytes (Figure S1). HSPGs including
syndecans-1 are actively shed from epithelial cells via the activity
of a variety of MMP sheddases including, but not limited to,
MMP7, MMP9, MT1MMP, ADMTS1, ADAM17, and LasA
(Figure 1Ai) [25,31]. Therefore, we hypothesized that HSPG-
bound HPV particles would be released from cells in complex with
HSPGs and syndecan-1. To test this theory we collected media
from HaCaT cells growing in complete medium (CM; DMEM
containing 10% FCS), including cells exposed to HPV16 PsV, and
assayed for released syndecan-1 and HPV. Immunoblot analysis
for syndecan-1 showed that CM itself contained substantial levels
of syndecan-1 (not shown). This finding complicated the
determination of virus binding effect on syndecan-1 release. To
avoid the issue of free syndecan-1 in CM, we used serum-free
medium (SFM) or Tyrode’s buffer solution (see Materials and
Methods). Cells starved in SFM were exposed to HPV16 at 4uC
and analyzed for syndecan-1 release after 6 h maintenance in
Tyrode’s buffer at 37uC. Immunoblot showed that cells released a
truncated form corresponding to the syndecan-1 ectodomain,
whereas the monoclonal antibody detected the SDS-stable dimeric
form of syndecan-1 form in cell lysates (Figure 2A). HPV did not
appear to accelerate syndecan shedding as reported for several
bacterial pathogens [32].
Author Summary
A subset of the .120 different types of human papillo-
maviruses (HPVs) are the most common cause of sexually
transmitted infections. Certain HPVs are also associated
with approximately 5% of all cancers worldwide. Like many
pathogens, HPVs bind first to heparan sulfate proteogly-
cans (HSPGs) on cells before moving to more specific
uptake receptors. However, relatively little is known about
the mechanism(s) that triggers the translocation of HPV
from HSPGs to the receptors that facilitate entry. As
obligate parasites, viruses have evolved numerous means
to hijack host cell functions to cause infection. We report
two novel mechanisms of pathogen-host interactions.
First, bound HPV particles are liberated from cells in an
active complex with HSPGs and growth factors rather than
dissociating from the sugars to engage secondary
receptors. Second, HPV uses the specificity of the
associated growth factors to bridge to their cognate
receptors as opposed to direct binding to a cell
internalization receptor. Signals transduced during these
interactions are important for HPV infection. Our study
provides new insights into the transmission of a significant
viral pathogen and reveals novel means whereby microbes
may repurpose normal cell functions during infection of
their hosts. Likewise, this work uncovers new targets for
HPV prophylaxis.
Infectious HPV-HSPG-Growth Factor Complexes
PLoS Pathogens | www.plospathogens.org 2 February 2012 | Volume 8 | Issue 2 | e1002519To characterize HPV16 released from cells, media from virus-
exposed cells were concentrated with Amicon 30 ultra-filters then
applied on a Sepharose 4B column. This method is used widely to
isolate and characterize differently sized complexes [33]. Size-
exclusion chromatography fractions were analyzed by SDS-PAGE
and immunoblot. As expected based on the large MW of the virus,
HPV16 eluted in void volume fractions of this highly porous gel
(fraction 4 contains large complexes or particles with
MW.10
7 Da) [34] (Figure S2). Immunoblot analysis of void
volume fractions revealed that the amount of HPV released into
the medium increased with time (Figure 2B). There are at least two
explanations for release of bound HPV16 from the cell surface in
CM. First, the non-covalent association of HPV to HSPG is
dynamic and viral particles could dissociate from the cell and
associate with soluble high concentrations of competing syndecan-
1 in the serum-containing CM. Second, HPV could be released in
complex with syndecan-1 or HS via the activity of MMP cleaving
the anchored ectodomain of the HSPGs or by heparinases
liberating HS. The second scenario is consistent with our finding
that syndecan-1 and HPV16 are released in Tyrode’s buffer,
which is devoid of soluble syndecan (Figure 2A and not shown,
respectively). If HPV exposure leads to increased MMP activity,
gelatin zymography analysis should reveal a higher level of
gelatinases in experimental medium in the presence of virus.
However, this sensitive and widely used method detects non-active
latent MMP forms in addition to active forms [35], and failed to
show a change in MMP levels when virus was present (Figure 2C).
Therefore, to more specifically test the involvement of MMP
activity in HPV release and infection, we investigated the effects of
MMP inhibitors on virus release and infection. The large number
of MMPs important for epithelial cell HSPG ectodomain shedding
and fact that many posses overlapping substrates in vitro make
genetic knockdowns unfeasible [36]. Since we wished simply to
determine if HSPG release was related to HPV16 infectivity, we
tested broadly active MMP inhibitors, batimastat (BM) marimastat
(MM), and tissue inhibitor of metalloproteinases 3 (TIMP3) that
are typically used to assay the functional consequences of
inhibiting MMP activity and the release of their substrates
[25,31]. Whereas TIMP3 broadly inhibits ADAM-TS4 and
ADAM-TS5 and all MMPS tested to date, BM is specific to
MMP -1, -2, -3, -7 and -9; MM blocks function of MMP -1, -2, -7,
-9, -14. These widely used hydroxamic acid MMP inhibitors are
well known to block the release of syndecans from cells when used
at .1 mM concentrations [37–39]. Both BM and MM effectively
Figure 1. Normal HSPG biology and proposed model for extracellular interactions of HPVs in the context HS-GF complexes. (A).
Natural processes of HSPG shedding that occur in the absence of HPV. The lower edges of epithelial cell lipid bilayers are depicted interacting with
the extracellular matrix (ECM). The ECM consisting of (e.g.) collagens, elastins, fibronectins, laminins is shown in pink. Laminin 332 (formerly laminin 5;
orange) interacts with syndecan-1 (purple) and alpha-6 beta-4 integrin (dark blue) on the cell surface to provide cell anchorage to the ECM/basement
membrane. Notably, these three molecules have been identified as HPV attachment factors (refs. in text). (i.) Sheddases including matrix
metalloproteinase (MMP) and ADAM (a disintegrin and metalloproteinase) sheddases (green) normally catalyze the release or ‘‘shedding’’ (dotted
arrows) of membrane-bound growth factors (GFs; light blue) and other bioactive molecules, the protein ectodomains of HSPGs like syndecan-1, and
ECM residents like laminin 332 [27]. (ii.) HSPGs in the plasma membrane and ECM act as local depots for soluble GFs and other bioactive molecules.
The HS-GF and bioactive compounds can interact with their cognate receptors laterally, via soluble form after release (iii), or in the ECM when cells
migrate over the HSPG-complexes. (iii.) Sheddases including MMPs and heparanases and proteolytic processing of laminin 332 liberate soluble
complexes containing GFs and HS/syndecan-1. (iv.) Soluble HS-GF complexes bind to GFR/RTK (yellow) and activate intracellular signaling cascades.
(B). The natural processes of HSPG decoration and release from the cells also occur in the presence of HPV particles (red). The virion image is based
on the atomic structure from Modis et al. [109]. By virtue of interaction with HS, HPV can join the complex at each stage where HSPG is involved (i–iv).
HPV could associate with soluble HS-GF in a naı ¨ve infection site or during release from infected cells (v.). HPV association with syndecan-1 via HSPG
and binding of syndecan-1 to laminin 332 and alpha-6 beta-4 integrin are consistent with the fact that HPV particles colocalize and interact with each
of these extracellular molecules. The abundance of HSPG in the ECM can explain why HPVs bind at such high levels to the ECM (ii.). Cells can pick up
HPV-HS-GF complexes in soluble form or by migrating over ECM-bound HPV-HS-GF complexes.
doi:10.1371/journal.ppat.1002519.g001
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efficiently reduced HPV16 infection of HaCaT cells (Figure 2F).
TIMP3 also prevented HPV16 infection (Figure 2F), but due to
lower MMP specificity was not investigated in other assays. A
dose-response analysis of BM and MM revealed HPV16 infection
inhibition at an IC50 of 400 nM (BM) and 1 mM (MM) in the
absence of visible toxicity (Figure S3). Thus, the actions of the
inhibitors indicate that MMPs are involved the release of virus
from cell membranes and that virus release plays an important role
in infection.
HPV particles released in HMW complexes are associated
with syndecan-1, HS and growth factors
Syndecan HSPGs participate in assembling signaling complexes
by accumulating biological mediators including GFs and present-
ing these factors to their high affinity receptors [40]. Therefore, we
predicted that released HPV particles would be in complex with
HS (or HSPG) of varied sizes along with assorted GFs.
Solubilization of the Sepharose 4B void volume fraction
(MW.10
7 Da) in SDS-mercaptoethanol sample buffer and
boiling caused dissociation of virus resulting in a ,55 kDa band
of HPV16 L1 protein (Figure 2B). We found temperature to be
crucial for viral complex dissociation; without heating, HPV16 L1
in SDS-reducing buffer was detected only in a form .150 kDa
(Figure 3A). These results indicate the cell surface-released HPV is
part of a detergent-resistant and temperature-sensitive HMW
complex. To determine the role of HS in this complex, the
Sepharose 4B void volume fraction was exposed to heparanase III.
Treatment with heparanase III induced partial dissociation of
HMW complexes and a considerable amount of soluble HPV16
L1 was detected at ,55 kDa, indicating that HS is involved in
formation of HMW virus-containing complexes. Under non-
reducing conditions in HMW fractions, HPV16 L1 migrated well
above 250-kDa (Figure 3B) demonstrating the reducing conditions
caused dissociation of some complexes. This is in contrast to the
fact that L1 proteins from purified mature HPV PsV appear as
125 kDa dimers and 195 and 215 kDa trimers under non-
reducing SDS-PAGE conditions, but never migrate above
215 kDa [41].
Next we used the HMW void volume Sepharose 4B fraction for
analysis of GFs and HS. Individually these molecules are low
molecular weight and mainly elute from the column in later
fractions (.9, Figure S2B). Fractionated media from mock
exposed HaCaT cells was a control. Immunoblot revealed the
presence of amphiregulin (AREG), heparin binding epidermal
growth factor (HB-EGF), EGF, HS, and syndecan-1 but only in
HMW fractions of media from cells exposed to HPV16 (Figure 3B).
Non-reducing SDS-PAGE of this void volume Sepharose 4B
fraction showed all of these molecules were present, each
appearing to be $250 kDa in size. To more specifically assess
the direct association of these components, we performed an IP for
HPV16 particles released into CM following virus binding to cells
at 4uC and shift to 37uC for 6 or 24 h. Immunoblot for HB-EGF,
EGF and syndecan-1 demonstrated these factors were in a
complex with HPV16 released from cells (Figure 3C). These
findings indicate HPV particles released in HMW complexes from
cells are ‘‘decorated’’ with syndecan-1 ectodomains, HS, and
assorted GFs. Although post-attachment release of incoming virus
has been reported for some retroviruses [42–45], to our knowledge
this is the first demonstration of an attached incoming non-
enveloped virus being liberated from the cell surface into the
experimental medium. Further, this is the first report of a
Figure 2. HPV16 and syndecan-1 release from the HaCaT cell plasma membrane is MMP dependent. Immunoblot for syndecan-1 (snd-1)
post starvation in SFM and after 6 h at 37uC in Tyrode’s Buffer (A); immunoblot for HPV16 L1 released into CM post virus binding for indicated times
(B) or 24 h (D). (C) Gelatin zymography showing protease activity present in HaCaT cell CM alone or with binding of HPV16. (D–F) Effect of MMP
inhibitors batimastat (BM) or marimastat (MM) at the indicated concentrations on HPV16 release into media as in panel B and densitometric
quantification with AlphaEaseFC software (E) and relative infection levels (F). Cells were untreated (U) or pre-treated with the indicated
concentrations of BM, MM or TIMP3 for 1 h, then exposed to HPV16 PsV in the presence of inhibitors in CM. Panel D includes lanes spliced together
from the same exposure of the same films. (F) Infection was assayed by quantifying luciferase levels at 24 h p.i. Data are represented as mean 6 SEM
of 3 experiments.
doi:10.1371/journal.ppat.1002519.g002
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released from cells.
Released HPV16 complexes are infectious and HSPG play
a crucial role in infection
To ascertain if released virus complexes were infectious, we
designed a co-culture transwell system wherein unexposed
(‘‘recipient’’) cells were cultured in chambers below an insert
holding ‘‘donor’’ cells that separately had been exposed to HPV16
(Figure 4A–D). As a proof-of-principle, HaCaT cells were tested as
both donor cells and recipient cells (Figure 4E). HaCaT donor
cells were allowed to bind HPV16, washed to remove unbound
virus and placed atop recipient HaCaT cells where they were
incubated with gentle rocking for 24 h. Comparable infection
levels were detected between directly PsV-exposed HaCaT donor
cells and the recipient HaCaT cells grown in the lower chamber
demonstrating the infectivity of the released HPV16 material
(Figure 4E).
To verify that HPV16 released from donor cells was in a
complex with syndecan-1, we used bead-attached anti-HPV16
antibody instead of recipient cells in the lower chamber. Following
capture of the viral particles, non-reducing SDS-PAGE and
immunoblot for syndecan-1 confirmed the co-IP of syndecan-1
with released HPV16 (Figure 4F). Similar to when the material
released into cell media was subjected to chromatography
(Figure 3), the syndecan-1 plus L1 complex released from donor
cells appeared as a HMW form $250 kDa. Conversely, only the
35-kDa monomeric form of syndecan-1 was detected via this rabbit
antiserum in the cell lysate from cells not exposed to HPV
(Figure 4F).
To determine the importance of HS in the infectious process
following PsV release, we tested wild-type Chinese hamster ovary
(CHO-K1) cells and mutant CHO cells defective in HS
biosynthesis (pgsd-677) [46]. Consistent with previous reports
[18,47], we found the HSPG-defective cells could be infected by
HPV16 PsV, but at levels reduced to only <5–8% of the wild-type
CHO cells (Figure 4G). Using our co-culture system, PsV-exposed
CHO-K1 or pgsd-677 donor cells were placed atop of CHO-K1
or pgsd-677 cells grown as recipient cultures. Infections were
assayed in paired donor and recipient cells from these co-cultures
(Figure 4G and H, respectively). Donor CHO-K1 cells exposed to
HPV16 PsV could fully confer infection to recipient CHO-K1
cells (Figure 4H, white bar). Importantly, recipient pgsd-677 cells
were also fully able to support infection, but only when CHO-K1
cells were used as PsV donors (Figure 4H, blue bar). These results
demonstrate for the first time that HSPG attachment receptors are
not required for recipient cell infection when HPV particles are
released in complex with HSPG from donor cells that are able to
express HSPG. These data show an essential infectious role for the
released HMW complexes containing HPV16 decorated with HS
on cells that lack HSPG. That donor pgsd-677 cells could confer
limited infection to CHO-K1 cells (Figure 4H, black bar) may
reflect low level dissociation or release of virus to the fully receptive
HSPG-wild type CHO-K1 cells.
Figure 3. Sepharose 4B gel chromatography of media constituents from HPV-exposed HaCaT cells. Sepharose 4B chromatography was
performed on released components in the CM of HaCaT cells exposed to HPV16 PsV for 4 h; see Figure S2. (A) The void volume (HMW) fraction was
divided into four parts that were untreated or incubated with 1 U heparinase III for 2 h at 37uC then solubilized in 66sample buffer and incubated at
25uC or boiled for 7 min before SDS-PAGE and L1-immunoblot analysis. Separate lanes shown are from the same exposure of the same film. (B) Non-
reducing SDS-PAGE of void volume Sepharose 4B fractions from released components in the CM of HaCaT cells mock-exposed or HPV16-exposed for
24 h. Immunoblot analysis was done to detect L1, amphiregulin (AREG), HB-EGF, EGF, HS and syndecan-1 (snd-1). (C) Non-reducing SDS-PAGE of
released components following IP of HPV16 from CM of HaCaT cells mock- or HPV16-exposed. HPV16 exposed cells were allowed to bind virus at 4uC
for 1 h, washed to remove unbound particles, then shifted to 37uC for 6 h or 24 h. CM were subjected to IP for HPV16 using affinity purified
polyclonal anti-HPV16 VLP antibody covalently attached to magnetic beads. Immunoblot analysis was performed to detect HB-EGF, EGF, and
syndecan-1.
doi:10.1371/journal.ppat.1002519.g003
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We hypothesized that if specific GFs were present in association
with HS-decorated virus, the very high affinity of GFs for their
specific receptors (KD<10–100 pM) might permit the GF to
determine the fate of the virus-cell interaction prior to HPV entry.
If supported, we should detect interaction of virus with GF
receptors (GFR). Co-localization of HPV16 with GFs and GFRs
was assayed by confocal microscopy and physical associations were
tested by co-IP. HaCaT cells exposed to HPV16 were either
incubated with fluor-labeled EGF or immunostained for KGFR.
Figure 5A,B shows the partial co-localization of HPV16 with EGF
and KGFR on the cell plasma membrane. IP of HPV16 PsVs
provided additional evidence of interactions with EGFR and
KGFR following PsV binding to HaCaT cells. Immunoblot
demonstrated the co-IP of EGFR and phospho-KGFR from
HaCaT cells following the IP of HPV16 PsVs (Figure 5C). These
data confirm the interaction of HPV16 with EGFR and KGFR on
the plasma membrane of human keratinocytes. The chromatog-
raphy and IP data together support the idea that HPV particles
become decorated with HS and bioactive molecules like GFs to
interact with GFRs.
HPV exposure induces rapid GFR phosphorylation and
activation of downstream effectors
The engagement of GFRs by their ligands induces rapid auto-
phosphorylation and downstream signaling. To investigate the
involvement of EGFR and KGFR activation and signaling in
HPV infections, we analyzed phosphorylation levels of the GFR
and mitogen-activated protein kinases (MAPKs) ERK1/2, key
enzymes of their pathways [29,48]. HaCaT cells starved in SFM
for 4 h were incubated with low doses of HPV PsV (10–20 vge/
cell) to avoid non-specific events; phosphorylation of target
proteins was determined by immunoblot analysis. Consistent with
receptor-ligand kinetics, GFRs were rapidly activated within
10 min of treatment with ligands (GFs or HPV16) inducing
concomitant phosphorylation of the downstream effector ERK1/2
(Figure 6A). Phospho (p)-EGFR (Y1173) levels induced by HPV16
were considerably lower compared to the effect induced by EGF.
The Y1173 site of EGFR is involved in MAPK signaling, and
importantly, the phosphorylation levels of p-ERK1/2 induced by
HPV16 were comparable to the effect of EGF (Figure 6A).
Treatment with a potent inhibitor of EGFR (PD168393), a pan-
FGFR inhibitor (PD173074), or the general receptor tyrosine
kinase (RTK) inhibitor, genistein, before exposure to GFs or
HPV16 diminished the rapid phosphorylation of the target GFRs
and downstream p-ERK1/2. KGFR activation of ERK1/2 can
involve EGFR cross talk and activation [49,50], which may
explain why EGFR inhibitor PD168393 fully blocks ERK1/2
activation by HPV16 when it also appears KGFR signaling is
initiated by the virus. In contrast, daidzein, a genistein analog that
lacks RTK blocking activity, did not inhibit HPV16-induced
signals (Figure 6A). To specifically query ligand-dependent EGFR
activation by HPV16, we investigated the effects of cetuximab, an
EGFR-specific monoclonal antibody that binds to the EGFR
extracellular domain with a higher affinity than ligands EGF or
TGF-alpha. Cetuximab inhibits EGFR phosphorylation and
Figure 4. Released HMW complexes including HSPG and HPV16 are required for infection. (A–D) Schematic of the ‘‘donor’’ cell/
‘‘recipient’’ cell co-culture system indicating how cells were exposed to PsVs. PsVs were allowed to bind donor cells without internalization (A). Donor
cells on coverslips were washed thoroughly to remove unbound PsVs and transferred to mesh inserts above the recipient cells (B) to co-culture with
gentle rocking for 24 h and allow released HPV complexes from donors to access the recipient cells (C–D). All experiments employed CM. (E) Relative
HPV16 infection levels of HaCaT donor cells and recipient HaCaT cells compared to mock infected cells as verification of the co-culture virus release
model. (F) Non-reducing SDS-PAGE and immunoblot of syndecan-1 (polyclonal rabbit antisera) following IP of HPV16 (mouse monoclonal anti-L1). IP
was performed by immobilizing anti-L1 in the lower chamber in place of cells (see panel B) to capture HPV16 released from mock exposed cells (M) or
HPV16-exposed HaCaT donor cells at 2 or 20 h post virus exposure. Lower panel IgG detection is included as a loading control. (G) Relative infection
levels in CHO-K1 and pgsd-677 cells used as donor cells bound to HPV16 PsV and co-cultured above the recipient cells. (H) Relative infection levels in
CHO-K1 and pgsd-677 cells used as recipient cells co-cultured below the PsV-bound donor cells corresponding to the data in panel G. Infectivity data
(E,G,H) were normalized to the mean value of the infected control set to 100% and represent the mean 6 SEM of 4 replicate infections.
doi:10.1371/journal.ppat.1002519.g004
Infectious HPV-HSPG-Growth Factor Complexes
PLoS Pathogens | www.plospathogens.org 6 February 2012 | Volume 8 | Issue 2 | e1002519activation and leads to receptor internalization and degradation
[51]. We found that cetuximab fully abrogated EGF- and HPV16-
induced phosphorylation of EGFR and p-ERK1/2 in this assay
(Figure 6B).
GFs strongly activate ERK1/2 proteins [52] and upon
stimulation, a significant population of these kinases moves from
the cytoplasm into the nucleus [53]. P-ERK1/2-specific immu-
noblotting of nuclear protein fractions and confocal microscopy
each revealed nuclear movement of p-ERK1/2 upon virus-
induced activation (Figure 6C,D). The timing of the p-ERK1/2
nuclear migration induced by HPV16 exposure reached maxi-
mum <10 min post exposure and indicates signaling pathways are
activated as early as 5 min post virus-host interaction. These
results agree with the report showing that even low-level EGFR
activation can fully induced ERK1/2 signals in human keratino-
cytes [54].
GFR inhibitors hinder HPV infection
To evaluate the importance of GFRs and tyrosine kinase
activation in HPV infection, HaCaT cells were incubated with
HPV PsV following pretreatment with and in the presence of a
reversible (AG1478) or an irreversible (PD168393) EGFR-specific
inhibitor, genistein, cetuximab, and an FGFR inhibitor
(PD173074) in CM. Both EGFR specific biochemical inhibitors
substantially blocked infection by HPV16 ($50%), while genistein
almost completely inhibited infection (Figure 7A). Treatment of
HaCaT cells with an EGFR blocking antibody (cetuximab) or
FGFR/KGFR inhibitor (PD173074) reduced infectivity by 50 and
35%, respectively. Similar GFR signaling activation and response
to inhibitors was observed with HPV31 PsV and with particles
carrying the viral genome (not shown; [55]), ruling out a luciferase-
specific inhibition. The complete inhibition of HPV infection by
preventing RTK signaling with genistein demonstrates the
requirement for this class of receptors in HPV infection. Specific
inhibitors of EGFR (cetuximab, AG1478, PD168393) or of KGFR
(PD173074), while completely abrogating signaling from their
respective RTK under brief starvation conditions described in
Figure 6, only partially reduced HPV infection under conditions in
CM (Figure 7A). These data show that no single RTK is essential
for HPV16 infection of HaCaT keratinocytes; rather, EGFR,
KGFR, and potentially other RTK are important mediators of
HPV infection. A genetic approach using siRNA to inhibit EGFR
expression gave complementary results. Typical transfection
efficiency of HaCaT cells was <70% as monitored by fluoresce-
in-labeled control siRNA. EGFR knockdown was assessed by
immunoblot in four separate transfections at 48 h post transfection
and ranged from remaining EGFR expression of 77% to 36%
compared to cells transfected with a nonspecific control siRNA
(Figure 7B). HPV16 PsV infections were performed 24 h post
transfection in matching replicates. Infection levels measured 24 h
later were reduced in a dose-dependent manner that closely
paralleled the level of EGFR knockdown (Figure 7C).
Because progression into early M-phase is needed for HPV
infection [56], it was important to assess whether the inhibitors
prevented infection via cell cycle blockade. Therefore, we assayed
the fraction of cells in each phase of the cell cycle during the
inhibitor treatments under which infections were determined
above. Although every condition affected the cell cycle distribu-
tion, in no case did an inhibitor arrest the cells in any one cell cycle
phase. Further, we found no correlation between infection
Figure 5. HPVs interact with growth factors and growth factor receptors on human keratinocytes. Immunofluorescent confocal co-
localization (arrowheads show examples of signal overlap) showing top view and side views of non-permeabilized HaCaT cells. (A) Co-localization of
HPV16 (red) with EGF (green). Bars measure 10 mm. (B) Co-localization of HPV16 (green) with KGFR (red). Bars=5 mm. (C) SDS-PAGE and immunoblot
for EGFR or p-KGFR after IP of HPV16 from HaCaT cells exposed to PsV. Lane 1, HaCaT cell lysate (without HPV exposure) incubated with anti HPV
antibody attached to magnetic beads (negative control); lane 2, IP of HPV16 (mouse monoclonal anti-L1) from virus-exposed HaCaT cells; lane 3,
blank; lane 4, HaCaT cell lysate following EGF exposure as positive control.
doi:10.1371/journal.ppat.1002519.g005
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employed (Figure S4). For example, the distribution of cells in the
G1, S, or G2/M phases of the cell cycle were relatively similar
whether cells were grown in CM and infected with HPV16 with
no treatment or treated with batimastat, marimastat, PD173074,
PD168393, or cetuximab. However infection levels ranged from
0% decrease with no inhibitor to nearly 90% reduction with
marimastat (Figure 2E). Specifically, the moderate changes
observed in the number of cells in G2/M phase were not sufficient
to account for the levels of infection inhibition demonstrated for
each inhibitor tested. The most striking result was found when
using monastrol, which increases the number of cells in late M-
phase and promotes infection [56] (Figure 7D). When PD168393
treatment was added with monastrol, a similar cell cycle profile
was seen, yet infection was dramatically inhibited by <70%
(Figures S4 and 7D, respectively). These data indicate that cell
cycle effects cannot account for the inhibition of early infection
events by these various compounds.
Serum enhances HaCaT cell infection with HPV
The cell binding and infectivity of some viruses are affected by
medium composition [57,58]. We also found HPV infection of
HaCaT cells to be dependent upon the nature of the experimental
media. Equal doses of HPV16 were allowed to attach to serum-
starved cells in SFM at 4uC and, after washing away unbound
virus, cells were incubated at 37uC overnight in SFM or CM. As a
positive control HaCaT cells were used where virus binding and
infection were both performed in the presence of CM. As shown in
Figure 6. HPV16 activates EGFR and KGFR signaling pathways. (A–B) Immunoblot for p-EGFR, p-KGFR and downstream effector p-ERK1/2
following 10-min ligand exposure (lane 2; listed at the left of each blot: EGF, KGF, HPV16 PsV) in HaCaT cells serum-starved for 4 h. Mock exposed cells
were negative controls (lane 1); ligand controls included 10 ng/ml EGF and 10 ng/ml KGF; HPV16 PsV dose was 20 vge/cell. Cells were pretreated
with the indicated inhibitors in Tyrode’s buffer (100 nM PD168393, 1 mM PD173074, 100 mM genistein, 100 mM daidzein, 600 nM cetuximab) and
exposed to the ligands in the presence of inhibitors Tyrode’s buffer. Actin is detected as a loading control. (C–D) Immunoblot of nuclear cell fractions
and confocal microscopy localization of p-ERK1/2 following EGF and HPV16 exposure in serum-starved HaCaT cells at indicated times post-exposure.
(C) Immunoblot for p-ERK1/2 in nuclear fractions from exposed cells. (D) Immunofluorescent confocal microscopy for localization of p-ERK1/2 (red) in
PsV exposed cells. DAPI was used as a nuclear marker and was pseudocolored green to facilitate efficient co-localization of p-ERK1/2 in the nucleus.
Parameters of lasers intensities were kept constant during the imaging.
doi:10.1371/journal.ppat.1002519.g006
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positive control and cells where virus was bound to cells in the
presence of SFM and thereafter incubated with CM. This
demonstrates that virus binding to initial attachment factors is
unaffected by the nature of the media. The addition of serum
(containing various GFs and HSPGs) to media significantly
increased virus infection, indicating an important role for these
molecules in virus uptake and infection. As we found that CM
contains considerable amounts of syndecan-1, likely in complex
with GF [40], we predicted depletion of syndecan-1 from the CM
would remove a substantial level of components needed for
infection. As expected, when the CM was stripped of syndecan-1
by IP, infection levels were reduced to levels close to those in SFM
(Figure 7E). Similarly, depletion of EGF from the serum also
robustly reduced infection levels (Figure 7E).
Based on our finding that bound HPV particles become
decorated with HS and are released from cells plus the fact that
main constituents of serum include albumin and GF, we
performed the reciprocal experiment and tested whether GFs
facilitate infection. If GFs are responsible for bridging the soluble
HMW HPV-HSPG complexes to secondary receptors, then
reconstituting GF in SFM should restore infectivity. Although
the addition of albumin did not enhance infectivity in SFM (not
shown), the addition of EGF and KGF in SFM dramatically
restored infection in dose dependent manners. EGF was able to
fully restore infection levels but KGF at the same concentrations
was only able to partially restore infection levels to those seen in
CM (Figure 7F). Thus, we show syndecan-1 plus either EGF or
KGF are required for HPV16 infection of human keratinocytes.
Although infection in SFM increased the number of cells in G1
phase, the depletion conditions did not alter the cell cycle profiles
significantly from that in CM or in SFM plus EGF (Figure S4),
suggesting cell cycle changes alone could not account for infection
inhibition.
Discussion
Intracellular pathogens like viruses hijack many normal cellular
processes in order to gain entry into a host cell [5]. Some viruses
have multiple structural proteins that are required to initiate
cellular uptake, whereas other viruses use one or two viral capsid
proteins for interaction. Certain viruses bind directly to uptake
Figure 7. GFR activation, EGFR expression levels, and serum components including GFs are important for HPV16 infections. (A)
Relative HPV16 infection of HaCaT cells in the presence of specific GFR and protein tyrosine kinase inhibitors. Subconfluent HaCaT cells were pre-
treated 45 min with 1 mM AG1478, 100 nM PD168393, 100 mM genistein, 100 mM daidzein, 1 mM PD173074, or 100–600 nM cetuximab. Cells were
exposed to HPV16 PsV at 100 vge/cell for 1 h at 4uC, then washed extensively and shifted to 37uC in the presence of the indicated inhibitor in CM for
24 h at which time they were analyzed for luciferase expression. Data are represented as mean 6 SEM of 3 experiments. (B–C) EGFR knockdown in
EGFR-siRNA transfected HaCaT cells was determined by immunoblot and compared by densitometry to EGFR levels in cells transfected with a
negative control siRNA at 48 hours post transfection. Four separate transfections were analyzed (B) and HPV16 PsV infection levels were measured at
24 h post infection (48 h post transfection) (C). Error bars represent the average of triplicate luciferase readings from the four transfections. (D) HPV16
PsV infection levels (24 h post infection) in the presence of inhibitors following pre-treatment for 1 hr with 100 mM monastrol, pre-treatment with
monastrol for 1 h plus 500 nM PD168393 for duration (monast.+PD), or pre-treatment with 500 nM PD168393 for 1 hr plus 100 mM monastrol for
duration (PD+monast.). (E) Relative HPV16 infection is dependent upon medium constituents post primary HPV16 binding. HaCaT cells starved in SFM
(4 h) were exposed to HPV16 in CM (positive control) or SFM. After washing away unbound virus, cells were incubated for 24 h in CM, SFM, syndecan-
1-depleted CM (IP-snd), or EGF-depleted CM (IP-EGF). Infections were quantified by luciferase assay at 24 h post shift to 37uC. Data are represented as
mean 6 SEM of 3 experiments. (F) Relative HPV16 infection in SFM is enhanced by GFs. HaCaT cells starved in SFM were exposed to HPV16 in SFM for
1 h at 4uC. After washing away unbound virus, cells were incubated for 24 h in SFM, SFM containing GFs (concentrations indicated: ng/ml), or in CM.
Infections were quantified by luciferase assay; bars represented the mean 6 SEM of $3 individual experiments.
doi:10.1371/journal.ppat.1002519.g007
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that are generally thought to lack specificity before particles are
laterally transferred to internalization receptors. In several cases,
early binding events may trigger capsid conformational changes
that permit virion movement to and/or interaction with an entry
receptor, dictate signaling to initiate endocytosis, and/or activate
membrane fusion activities for some enveloped viruses. Although a
variety of cellular interacting factors have been identified for the
HPV infection process, many specifics of the early stages of HPV-
cell interaction have been enigmatic. HPV particles engage HSPG
attachment moieties and are thought to dissociate from HSPGs or
to move laterally to interact with secondary receptors that promote
endocytosis. Yet, the mechanism facilitating virus movement from
primary attachment to the internalization receptor(s), or whether
the process is spontaneous or highly controlled, has not been
defined.
Syndecan-1, the predominant HSPG in keratinocytes, is a
demonstrated primary HPV-cellular interacting partner [18,19].
The HPV-HS interaction was first thought to be nonspecific, but
recent reports show that HS modifications by sulfate groups are
essential for HPV types 11, 16 and 33 capsid interactions with cells
[14,59]. HPV L1 proteins mediate the capsid binding to HSPG;
L1-only VLP are capable of normal cellular internalization [16]
and the L2 protein does not contribute to the initial interaction
[60]. It has been proposed that L1-HSPG binding induces
conformational changes in the viral capsid that cause the normally
hidden N-terminal region of L2 to become accessible to furin
cleavage [6]. This action on L2 is suggested to trigger reduced
affinity of capsids for HS [61]. However, the ability of L2 cleavage
to induce an L1 conformational change of the magnitude that
would cause dissociation from this strong interaction with HS is
difficult to envision and prompted us to investigate the means of
HPV movement from HSPG to secondary receptors.
Here we report evidence for a novel mechanism by which a
virus commandeers a normal cellular process, in this case to
transfer from general attachment factors to receptors responsible
for infection (Figure 1B). Our results show that HPV16 is not
dissociated from syndecan-1 HSPG, but is released from the cell
surface in complex with a shed form of HSPG that also carries GFs
and/or other bioactive compounds (Figure 1Biii). Although the
entirety of this transfer mechanism is a unique observation with
regard to viruses, various aspects of this process have been
reported for other intracellular pathogens. For example, infecting
retroviruses are shed from a cell-attached state, which, based on
their association with HSPGs, could be induced by the same
mechanism of cellular liberation we show here [42–45]. Chlamydia
trachomatis interacts with HSPGs for primary attachment to cells
and also with fibroblast growth factor 2 (FGF2) to promote
bacterial entry [62].
Extracellular domain shedding of proteins is involved in the
control of diverse cellular functions such as development, growth,
differentiation, and wound healing as well as various pathologies
like cancer [21,23,25,28,63]. For example, it has recently been
recognized that ectodomain shedding functions to control the
availability of EGFR ligands, TGF-beta receptor, TNF-alpha, and
cell adhesion molecules (L-selectin, E-cadherin). Members of the
EGF family are synthesized as a type-1 transmembrane protein
that can be enzymatically cleaved to release soluble 14–20 kDa
GFs (Figure 1Ai). Most of these soluble GFs are then concentrated
on the HS chain of proteoglycans (for example syndecans) and
shedding of these HSPGs appear to play modulatory roles, such as
by presenting the GFs to their high affinity cognate receptors to
activate signaling and receptor-ligand endocytosis [23,24]. Ecto-
domain shedding of membrane-bound proteins is mediated by
proteases known as sheddases. Among these enzymes, MMPs are
the predominant syndecan sheddases, but several other factors like
heparinases act cooperatively to regulate this process [21]. Here
we show that release of cell–bound HPV is regulated by MMPs
and inhibition of sheddase activity significantly decreases virus
release and infection. MMPs have been implicated in neoplastic
situations for some time, with several reports suggesting that HPV
early proteins play a role in the regulation of MMP expression and
activity [64]. The relationship between MMPs and HPV proteins
appears to be complex and further work will be necessary to fully
appreciate their interactions.
Following what we term as the HPV decoration process,
whereby viral particles associate with HSPG-bound GFs and are
liberated from cells via normal sheddase activity, the decorated
HPV particles act as soluble effectors of infection (Figure 1Biii).
The specificity of the GF or other bioactive molecule is used to
bridge and interact with the cognate cellular receptor (i.e., a
RTK/GFR) and induce signals needed for initiation of infection
(Figure 1Biv). As soluble HPV particle could be decorated with
various active molecules, there is no single RTK responsible for
internalization. Herein, we concentrated our attention on EGFR
and KGFR due to their important regulatory roles in keratino-
cytes. Our results clearly define activation of GFRs as a necessary
step in infection. Both of these receptors are rapidly activated by
interaction of HPV16 with HaCaT cells, and varied specific
inhibitors of the receptors block their phosphorylation. Moreover,
rapid phosphorylation of key downstream effectors of these
pathways (ERK1/2) was observed. This is in agreement with
recently published data showing fast activation of PI3K and FAK
kinase upon HPV16 PsVs binding to HaCaT cells [65,66].
Although we did not directly measure PI3K and FAK activation,
they are upstream of ERK1/2 in the signaling pathway and play
important roles in the regulation of these MAPKs. Specific
inhibitors of EGFR and FGFR only partially inhibit infection,
whereas genistein (a general tyrosine kinase inhibitor) completely
blocked infection of HaCaT cells with HPV16. These data support
our conclusion that there is no sole pathway essential for HPV16
infection; the virus could infect cells using multiple pathways and
receptors. Regulation of GFR activity during persistent HPV
infections is well known, and this is attributed to actions of virus
early proteins in infected cells [67,68]. Here we demonstrate that
even in the earliest stages of HPV-host cell interaction, and prior
to viral gene expression, oncogenic HPVs usurp mitogenic GFR
signal pathways that cause nuclear localization of ERK1/2.
Importantly, these signals cause activation of AP1 transcription
factors, c-fos and c-jun, which are important for HPV early
transcription and are thought to dictate the strict epithelial tropism
demonstrated by HPVs [69–71]. In this way, HPV interaction at
the cell surface, like that of many other viruses, primes the host cell
for viral gene expression and the establishment of infection.
The goal of this work was to determine how HPV moves from
HSPGs to initiate virus entry and we focused our analyses at the
plasma membrane. Although we have not unequivocally shown
GFRs to mediate virus endocytosis, several lines of evidence
support the idea that the GFRs can facilitate HPV entry. First, we
show HPV16 PsVs reside in a complex containing HSPGs and
GFs, and can activate GFR signaling in human keratinocytes soon
after PsV exposure. HPV particles associate with GFRs at the
keratinocyte plasma membrane and the removal of syndecan-1
HSPG or EGF inhibits infection. These observations strongly
indicate the virus interacts with GFRs to physically induce signals
and that this is not an indirect effect of virus exposure. Secondly,
interaction of bioactive HS-GF with their specific receptors
typically leads to receptor-mediated endocytosis following the
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reduced using a variety of RTK inhibitors and a genetic
knockdown approach. Lastly, many other intracellular pathogens
can use GFRs as internalization receptors, some via physical
bridging of GFs to their cognate receptors. EGFR can be used as
an entry receptor for vaccinia, cytomegalovirus, herpes simplex,
influenza virus, and hepatitis C virus [72–77]. Yet, in many cases –
just as we show for HPV16 – EGFR is not the sole entry receptor
for these pathogens. Furthermore, Chlamydia trachomatis uses FGF2
to engage the FGFR for uptake and a herpes simplex virus
engineered with an EGF ligand can bridge to cognate GFRs to
activate entry [62,78].
Our new model for the HPV infection process shown in
Figure 1B incorporates findings from a number of prior studies.
Importantly, our model facilitates the explanation of some
discrepancies in the literature regarding HPV-cell interactions
and entry. These include the nature of secondary receptor
interactions, disparate virus internalization rates and pathways,
and differences between infectivity of the viral particles obtained
from organotypic (raft) tissues and virus particles obtained from
the 293T expression system. Lastly, our findings fit well with the
observed importance of wounding in HPV infections, and may
have broader implications for pathogen-cell receptor interaction
via HSPGs and GFs.
Nature of the secondary receptor interactions, virus
internalization rate and pathways
Integrins, laminin 332 and syndecans have all been shown to
interact with HPVs [19,65,79,80]. Each of these interactions may
be primarily due to the association of HPV particles with HSPGs,
which are direct modifiers of syndecan-1 and interaction partners
with laminin 332 and alpha-6 integrin (as shown in Figure 1). We
demonstrated HPVs associate with HS molecules bearing various
GFs and interact with EGFR and KGFR. Together, our findings
indicate that binding of HPV to a secondary receptor depends on
the nature of active compounds decorating HPV.
Reported entry half times for HPVs range from 4 h to 24 h
[3,14,15,18,81,82]. Although we reported a 14 h internalization
half-time for HPV31 in HaCaT cells [82], we also detected
HPV31 early transcripts by RT-PCR as early as 4 h post infection
[83]. These observations suggest that some HPV particles are able
to enter via an infectious route much more quickly than others.
The findings in this current study and the normal biology of HS-
GF complexes lead us to reason that the protracted and variable
HPV entry timing is due to the multiple locations and ways that
virions can become decorated with HS-GF complexes (Figure 1B).
Particles decorated with HS-GF during isolation or potentially
associating with these soluble materials in serum (Figure 1Bv) may
be readily able to directly engage the entry receptor, effectively
bypassing the more time consuming steps of HSPG-GF interaction
and subsequent enzymatic release of HMW complexes. Our data
and reports from other labs showing RTK/GFR signaling can
occur minutes after virus exposure also support this idea
[65,66,84].
The preferential association of HPV with the ECM and
basement membrane appears to be due to interactions with
laminin 332 (formerly named laminin 5; Figure 1Bii) [17,80,85].
This is likely because laminin 332 is a depot for HS-GF complexes
to which HPV can attach [86], and these active complexes can be
liberated by heparinases and sheddases [87]. Our co-culture assay
does not differentiate between virus released from the cell surface
or the ECM. We previously reported the disappearance of ECM-
bound HPV over time [55] suggesting that the release of both
ECM- and plasma membrane-bound HPV-HS-GF complexes
could contribute to the infectious process. Thus, longer internal-
ization kinetics would be expected if some HPV capsids associate
with HS-GF by binding HSPG on the plasma membrane, or by
associating with the HS-GF complexes that are normally
sequestered on the ECM or the basement membrane. MMP- or
heparinase-mediated release of these HWM HPV-HS-GF com-
plexes would be required for subsequent engagement of the
secondary receptor (Figure 1Biv).
We propose the spectrum and diversity of the active compounds
(e.g., GFs) with which HPV-HS could interact clarifies why a
single secondary receptor responsible for virus internalization has
not been identified. Various active compound-virus complexes
bind to distinct receptors and consequently are internalized via
different endocytic pathways, which explains the internalization of
HPVs dependent on clathrin [15] or relying on caveolin [82,88],
as well as pathways independent of both clathrin and caveolin
[89]. EGFR and KGFR internalization are typically clathrin-
dependent. However, EGFR entry can also involve slower
clathrin-independent modes and EGFR associates with caveolae
and lipid microdomains, especially when coupled with alpha-6
beta-4 integrin [29,90]. Blocking ligand binding or the kinase
activity of these receptors with specific inhibitors clearly shows
significant roles for these GFRs in HPV infection. CHO cells lack
EGFR ErbB1, but are readily infected with HPVs, further
demonstrating the ability of HPV to utilize multiple routes of
infection. Similarly, vaccinia virus infection of HeLa cells is EGFR
dependent, yet the virus also infects CHO cells using an undefined
alternate mechanism [77].
Differences in HSPG dependence between tissue-derived
and 293T system-derived virus preparations
Previously, we showed that organotypic (raft) epithelial tissue-
derived HPV31 virions infect HaCaT cells in an HSPG-
independent manner [91], whereas HPV31 PsVs from the 293T
system are HSPG-dependent in the same cells (our unpublished
data and [85]). We speculate that the differences are due to a high
level of decoration occurring during virion isolation from the raft
tissues, which then allows raft-derived virions to bypass the need
for HSPG association on newly exposed naı ¨ve cells. This is based
on our finding that viral particles extracted from raft tissues are
substantially less pure relative to HPV particles obtained from the
293T expression system, likely due to the lower yields of virus
particles per cell in the raft system compared to the 293T model
[92]. It is probable that low-level HPV capsid decoration
occurring during assembly and purification from 293T cells
contribute to the basal levels of infection observed in the absence
of HSPG or serum components (Figures 4G, 7EF, refs. [18,47]).
Differences in HPV particle decoration due to isolation techniques
could result in quantitatively disparate phenotypes depending
upon the assays.
The possibility that other structural modifications with func-
tional consequences occur differentially during virion morphogen-
esis in the raft tissue culture system compared to particle assembly
in the 293T system cannot be discounted. Nevertheless, many
observations strongly support the biological relevance of differen-
tiation-independent (e.g., 293T cell-derived) HPV particles for
functional studies. Self-assembling VLP and PsV capsids contain-
ing L1 and L2 are structurally indistinguishable from wart-derived
HPV virions [93,94]. Of specific importance, L1-only HPV VLPs
mimic wart-derived virions functionally such that in vivo they elicit
neutralizing antibodies that confer long-term protection from
infection in animal models and in clinical trials [95,96]. Indeed,
these L1-only VLPs are the basis for the successful HPV vaccines
in use throughout the world today. Also of particular biological
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cotton tailed rabbit PV (CRPV) virions to 293T-produced CRPV
virions established that the virion stocks were essentially
indistinguishable as assayed by susceptibility to antibody-mediated
neutralization, papilloma induction, and gene expression within
lesions in rabbits [97]. HPV PsVs expressed from capsid genes of
carcinogenic HPV types like HPV16 have a number of advantages
over tissue-derived virions, especially given that virions for
carcinogenic HPV types have never been purified in valuable
levels from human lesions. High-titer, high-purity PsVs have utility
in a wider variety of assays and in more rigorously controlled
experiments than the more crude virions obtained from the
organotypic tissue culture system [92,98,99]. Thus, sound
evidence suggests that 293T-derived PsVs provide a functional
and practical substitute for working with high-titer carcinogenic
HPV virions in many situations [17,93,100].
Implications for in vivo infections in a wounded
environment
Epithelial wounding, an important mediator of HPV infections in
vivo [30], leads to the influx and activation of many cell factors shown
to interact with HPVs, including thosewe have identified in this work.
GFs, cytokines and chemokines are key mediators of wound repair.
EGF and KGF are released from cells, and heightened MMP activity
causes an increase in HB-EGF shedding (reviewed in [101]). EGF
and cytokines are involved in the regulation of syndecan shedding
[21] and KGF induces strong syndecan-1 expression beneath the
basement membrane [102]. Further, syndecan-1 expression is
strongly upregulated in migrating and proliferating keratinocytes.
Syndecan-1 and -4 ectodomains are found in acute dermal wound
fluids, where they regulate GF activity [103], specifically the
formation of HS-KGF complexes and actions of MMPs on shedding
of EGFR ligands [104]. EGFR expression transiently increases after
wounding [105] and KGFR is upregulated at the wound margin
[106]. Alpha-6 beta-4 integrin, the classic core component of
hemidesmosomes, performs adhesive functions by binding to laminin
332 in the basement membrane. Association of EGFR with alpha-6
beta-4 integrin and EGF-induced phosphorylation of beta-4 integrin
is important for this disassembly of hemidesmosomes to promote
cytokinesis and epithelial migration a wound-healing response
(reviewed in [90]). Taken together, our work illustrates additional
means by which HPV has adapted to utilize the environment created
during wounding, which not onlyallows the virus access to mitotically
active basal cells, but also provides factors essential for the virus to
infect cells with the boost of mitogenic signals.
In a broader sense, it is of particular interest to reiterate that
syndecans and other HSPG are bound by pathogens in addition to
HPV, including some retroviruses, herpesviruses, flaviviruses, and
bacteria like Chlamydia and Neisseria in their infection courses. Some
of these pathogens, as discussed above, are also known to activate
GFR pathways for infection. This brings up an exciting possibility
that these other pathogens might also employ a soluble virus-HS-
GF mode of infection under certain circumstances. Our study
provides new insights into the transmission of a significant viral
pathogen and reveals novel means whereby pathogens may
repurpose normal cell functions during infection of their hosts.
Likewise, this work uncovers new targets for prophylaxis of HPV,
and potentially other pathogen infections.
Materials and Methods
Cell culture, transfections, virus production, infections
The sources of different cell lines and their culture conditions,
plasmids used, procedures to produce and purify HPV PsV, and
the procedure for the exposure and infection of target cells are
provided as Supporting Protocols S1 and S2 in Text S1. 293T
cells, HaCaT cells, CHO-K1 cells and derivative pgsd-677 were
maintained as reported [46,83,107,108]. HPV PsVs encapsidating
a luciferase reporter plasmid were generated via transfection in
293T cells and quantified for vge and L1/L2 capsid levels. SDS-
PAGE and Coomassie Brilliant Blue staining were used to assess
the purity of virus stocks [92]. Under our transfection conditions,
capsids typically outnumber vge by 2- to 10-fold [88]. CsCl
gradient-purified PsV stocks were sonicated, added to cells in
various media and incubated at 4uC for 1 h to permit viral
attachment. Inocula were aspirated, cells were extensively washed,
and fresh culture media or Tyrode’s buffer (10 mM HEPES
pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2,1 m M
MgCl2, 5.6 mM glucose, and 0.05% BSA) were added. Infections
were allowed to proceed at 37uC, typically for 24 h before
luciferase quantification. For the co-culture viral release assay,
subconfluent donor cells grown on cover slips were incubated with
PsVs at ,2000 vge/cell for 1 h, 4uC (Figure 4A). Cells were
washed 3X to remove unbound PsVs, and coverslips transferred to
74-mm mesh plate inserts (Corning). The PsV-exposed donor cell
inserts were suspended above a subconfluent recipient cell
monolayer with media covering both cultures (Figure 4C). Donor
and recipient cell infections were measured by luciferase assay.
siRNA cell transfection was performed using Lipofectamine 2000
reagent (Invitrogen), with EGFR siRNA (Cell Signaling) according
to manufacturer’s recommendations. A nonspecific siRNA was
used as a negative control (Dharmacon). Transfection was
monitored using fluorescein-conjugated siRNA (Cell Signaling).
Scepter Cell Counting (Millipore) for viability and size and Trypan
Blue exclusion staining were used to measure cell viability.
Sepharose 4B gel chromatography and analysis of HMW
complexes
Cells were incubated with 200 vge/cell of PsV for 1 h at 4uC,
washed 3X with media and incubated at 37uC for various times.
Experimental media were cleared by low speed centrifugation and
the supernatant was concentrated by Amicon Ultra 30K filtration
(Millipore). Concentrated samples were fractionated on Sepharose
4B columns that had been preliminary calibrated with standard
proteins as described [34]. The samples were applied to an
equilibrated Sepharose 4B column and left for 3 min; eluate was
collected as fraction 1. PBS was applied and fraction 2 collected in
3 min and so on. Eluted fractions were analyzed by SDS-PAGE
followed by immunoblotting for HPV16 L1, proteoglycans and
growth factors. Additional details of chromatography are given in
Supporting Protocol S3 in Text S1.
Gelatin zymography
HaCaT cells were incubated overnight following exposure to
HPV PsV (100 vge/cell), culture supernatant was removed,
cleared by centrifugation and concentrated by Amicon filtration.
Concentrate was mixed with 66non-reducing sample buffer and
electrophoresed through a 8% acrylamide gelatin gel and analyzed
as reported [35].
Fluorescent staining and microscopy
HaCaT cells were seeded onto glass cover slips and cultured
overnight. Media were removed and the cells were starved for 2 h
with Tyrode’s buffer prior to PsV exposure at 4uC, 45 min.
AF488-conjugated EGF was added and incubated an additional
15 min. Unbound materials were washed out and cells fixed. After
extensive washes, cells were blocked and incubated with rabbit
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incubated with AF594-conjugated anti-rabbit IgG. Alternatively,
for visualization of KGFR and HPV co-localization, BSA-blocked
cells were incubated with anti-KGFR (FGFR2IIIb) mouse
monoclonal and a rabbit anti-HPV VLP antisera. PBS washed
slides were incubated with donkey anti-mouse-AF549 and AF488-
conjugated anti-rabbit IgG secondary antibodies. For detection of
ERK1/2, fixed cells were permeabilized prior to adding anti
phospho-44/42 MAPK rabbit monoclonal followed by Cy3-goat
anti-rabbit IgG. All images were acquired with a Zeiss LSM 510
META confocal system using appropriate filters. Detailed
immunofluorescence methods and antibody specifics are given in
Supporting Protocol S4 in Text S1.
IP and depletions
For co-IP of syndecan-1 from released material, HaCaT cells
were seeded and incubated with virus as in Figure 4A with anti-
HPV16 L1 mouse mAb attached to Dynabeads–Protein A in the
lower chamber (instead of recipient cells as in Figure 4C). After 2
or 20 h of incubation, beads were collected, washed, and
solubilized in non-reducing sample buffer. Syndecan-1 was
detected using rabbit anti-serum after SDS-PAGE by immunoblot
(details in Supporting Protocol S5 in Text S1).
GFRs were subject to co-IP with HPV16 PsVs bound to
HaCaT cells at 500 vge/cell at 4uC,1 h; mock-exposed cells were
a negative control. Cells were solubilized with cold Triton lysis
buffer (1% TX100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM PMSF, 10 ng/ml leupeptin, 10 ng/ml
aprotinin). Insoluble materials were removed by centrifugation
and supernatants were immunoprecipitated for 1 h at 4uC with
rabbit anti-HPV16 VLP antibody attached to protein A-magnetic
Dynabeads (Invitrogen Dynal). Soluble proteins were resolved by
10% SDS-PAGE and were transferred onto PVDF membranes,
which were probed with anti-syndecan-1, anti-HB-EGF, anti-
EGF, anti-EGFR, or p-FGFR and then HRP-conjugated
secondary Ab. To deplete syndecan-1 and EGF from media,
CM was incubated with anti-syndecan-1 mAb or anti-EGF mAb
attached to Protein G Sepharose beads for 3 h at RT. The media
was filtered to remove the bound material and used for infections.
As a negative control we used CM incubated with Protein G
Sepharose beads. Additional details of IPs are given in the
Supporting Protocol S6 in Text S1.
EGFR and KGFR signal activation
Subconfluent HaCaT cells were serum-starved for 3–4 h in
Tyrode’s buffer containing 0.05% BSA. After adding ,100 vge/
cell HPV16 PsVs, 10 ng/ml EGF or 10 ng/ml KFG, cells were
incubated at 37uC for 10 min before transferring to ice and
solubilizing cells with RIPA buffer. In some experiments cells were
incubated with various inhibitors in Tyrode’s buffer for 45 min
and after Tyrode’s washes, were incubated with virus as above in
the presence of inhibitors. Lysates were clarified, mixed with
Laemmli buffer and boiled for 5 min prior to SDS-PAGE.
Immunoblot was performed with various monoclonal and
polyclonal antibodies: p-EGFR, p-KGFR, p-ERK, actin.
For nuclear extractions, HaCaT cells were starved 4 h in
Tyrode’s solution containing 0.05% BSA, then exposed to HPV,
EGF or KGF for various times. Cells were solubilized with NP40
lysis buffer and centrifuged. The pellet was incubated with nuclear
extraction buffer. Following incubation on ice for 1 h, the extract
was clarified and the supernatant subjected to SDS-PAGE and
immunoblot for analysis of p-ERK content. Additional details and
buffer constituents are given in Supporting Protocol S5 in Text S1.
Effect of inhibitors on HPV infection
Subconfluent HaCaT cells were pre-treated 45–60 min with
1 mM AG1478 (Calbiochem), 100 nM PD168393 (Calbiochem),
100 mM genistein (Sigma), 100 mM daidzein (Sigma), 1 mM
PD173074 (Calbiochem), 100–600 nM cetuximab (ImClone),
1 mM to 100 mM MM (Tocris Bioscience) and 1 mM to 100 mM
BM (Tocris Bioscience). For dual inhibitor assays, cells were pre-
treated 1 hr with 100 mM monastrol, pre-treated with monastrol
plus 500 nM PD168393 for 1 h, or pre-treated with 500 nM
PD168393 for 1 hr prior of adding 100 mM monastrol and
incubated an additional 1 h. Cells were exposed to HPV16 or
HPV31 PsV at 100 vge/cell for 1 h at 4uC, then shifted to 37uCi n
the presence of inhibitors for 24 h at which time they were
analyzed for luciferase expression. These inhibitor concentrations
are well documented not to cause cell toxicity; cell viability was
$94% in each assay.
Supporting Information
Figure S1 HPV16 and HPV31 interact with HSPG and
syndecan-1 at the cell plasma membrane. (A–D) Immu-
nofluorescent confocal localization and 3D reconstruction showing
HPV16 or HPV31 (green) with heparan sulfate or syndecan-1
(red). PsV were added to cells at 5000 particles per cell. The bars
measure 5 mm. (E) IP of HPV16 from HaCaT cells exposed to
HPV16 PsV and immunoblot for syndecan-1 (mAb DL-101;
Santa Cruz). The bound PsVs and cells were either untreated or
membrane-bound proteins were cross-linked with DTSSP. Lane 1,
magnetic beads and anti-HPV16; lane 2, IP of HPV16 from
HaCaT cells; lane 3, IP of HPV16 from HaCaT cells treated with
DTSSP before lysis; lane 4, left blank; lane 5, HaCaT cell lysate
(no IP).
(TIF)
Figure S2 Analysis of Sepharose 4B chromatography of
released materials in CM of HaCaT cells exposed to
HPV16 PsV. Eluted fractions (indicated at top of gels) were
solubilized in 66 sample buffer, boiled for 3 min. Samples were
separated by 10% SDS-PAGE followed by electrotransfer to
PVDF membrane. Lanes are indicated below each blot.
Membranes were probed for (A) HPV16 L1 using mouse mAb
(Abcam) and (B) for syndecan-1 using a monoclonal antibody
(Santa Cruz). Lane 11 in Panel B contains HaCaT cell lysate as a
control.
(TIF)
Figure S3 IC50 of HPV16 infectivity inhibition by MMP
inhibitors batimastat and marimastat. HaCaT cells
incubated with serial dilutions of batimastat (BM) or marimastat
(MM) in CM for 1 h before incubation with 100 vge/cell HPV16,
1 h at 4uC. After washing away unbound virus, cells were
incubated for 24 h at 37uC in the presence of inhibitors. HPV16
infection was measured with luciferase assay. Error bars represent
SEM of three replicates.
(TIF)
Figure S4 Cell cycle changes induced by inhibitors
cannot account for observed HPV16 infection inhibition.
Pyeon et al. showed that progression through early M phase is
needed for HPV infection of HKs [56]. They also showed that
monastrol, which blocks in early M phase leads to an increase in
infection (as in Figure 7D). To investigate if infection inhibition by
the various agents used in Figure 7 could be attributed to cell cycle
changes, identical conditions and timing of inhibitor treatment on
HaCaT cells were assayed with propidium iodide and examined
using flow cytometry. The fractions of cells in G1 (1n), S
Infectious HPV-HSPG-Growth Factor Complexes
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percentages of the total cells counted.
(TIF)
Text S1 Supporting protocols.
(DOC)
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